Wednesday, July 8, 2026

Drug profile · INN

peramivir

peramivir (ALPIVAB) is a neuraminidase inhibitor. Associated with Biocryst. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved EMA: withdrawn Antiinfectives for systemic use (J05) J05AH03
US status approved
Patents linked 19
Pipeline programs 7
News articles 0
Drug details — peramivir
US status
approved
Class
Antiinfectives for systemic use (J05)
Route
INTRAVENOUS
Patents
19
Programs
7
Data quality
0.89

Quick answer

peramivir (ALPIVAB) is a neuraminidase inhibitor. Associated with Biocryst. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN peramivir
Brand ALPIVAB
Mechanism Neuraminidase inhibitor
Target Neuraminidase
Therapeutic class Antiinfectives for systemic use (J05)
Route INTRAVENOUS
Formulation SOLUTION
ATC code J05AH03
Originator Biocryst

Mechanism of action

Neuraminidase inhibitor

Primary target: Neuraminidase

Approval history

Authority Status Date
FDA approved
EMA withdrawn

Pipeline programs

  1. Peramivir Phase 3 · Biocryst · Seasonal Influenza
  2. Peramivir Phase 3 · Biocryst · Influenza
  3. Peramivir 150mg Phase 3 · Biocryst · Influenza
  4. Peramivir+SOC Phase 3 · Biocryst · Cough
  5. Peramivir Phase 2 · Biocryst · Acute, Uncomplicated Human Influenza
  6. Peramivir 150 mg Phase 2 · Biocryst · Influenza
  7. Peramivir 200 mg Phase 2 · Biocryst · Influenza

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)
  1. US 11559515

    Indole compounds and analogues thereof

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11173159

    Methods and compositions for inhibition of polymerase

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10849883

    Benzopyrazole compounds and analogues thereof

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 10420769

    Methods and compositions for inhibition of polymerase

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 10391075

    Antiviral treatments

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10022375

    Methods and compositions for inhibition of polymerase

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 9580428

    Compositions and methods for inhibiting viral polymerase

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 9492452

    Methods and compositions for inhibition of polymerase

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8778997

    Antiviral treatments

    Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8163703

    Hepatitis C therapies

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8133870

    Therapeutic furopyrimidines and thienopyrimidines

    Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 7514410

    Hepatitis C therapies

    Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 7429571

    Therapeutic furopyrimidines and thienopyrimidines

    Expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 7045535

    Compounds useful for inhibiting paramyxovirus neuraminidase

    Expires Mon May 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  15. US 6835326

    Fluorescent ink compositions comprising functionalized fluorescent nanocrystals

    Expires Mon Dec 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  16. US 6680211

    Fluorescent nanocrystal-embedded microspheres for fluorescence analysis

    Expires Mon Jan 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  17. US 6576155

    Fluorescent ink compositions comprising functionalized fluorescent nanocrystals

    Expires Mon Jun 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  18. US 6458799

    Deazaguanine analog, preparation thereof and use thereof

    Expires Mon Sep 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  19. US 6268350

    Polynucleotides for inhibiting metastasis and tumor cell growth

    Expires Mon Jul 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is peramivir?

peramivir (ALPIVAB) is a neuraminidase inhibitor. Associated with Biocryst. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for peramivir?

ALPIVAB is a marketed brand name for peramivir. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of peramivir?

peramivir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.